Access begins with Artia.
Artia Solutions launched over 32% of all drugs approved in the U.S. in 2023.
From drug launch strategy to supplemental rebate bid analysis to product access monitoring, we set the standard in Medicaid consulting.
Our Story
After several years in the pharmaceutical industry—and two years as the pharmacy director of Florida Medicaid—George Kitchens, RPh, saw a need for strategic Medicaid access consulting for drug manufacturers. The light bulb went off, and he founded Artia Solutions in 2005. The one-man show quickly grew into a full-fledged national Medicaid consulting firm with over 30 employees. Artia’s team of PharmDs and analysts holds more than 100 years of combined Medicaid policy, administrative, clinical, legislative, and budgeting experience.
Supporting Solutions
Our custom-built technology and curated tools assist our clients in effectively forecasting access upon launch, understanding coverage landscapes, and monitoring their products post-launch.
More on our products
The App
The Artia App, available for iOS and Android, provides Medicaid P&T and DUR meeting information and market share data for every state.
Learn More
Capsule
Capsule is our proprietary database that houses state-specific Medicaid information for pharmaceutical manufacturers.
Learn More
Featured Clients
Our clients range from new drug manufacturers with a specialty drug to drug manufacturers with an established portfolio. Regardless of company size or service level, we're dedicated to the hard work that a successful Medicaid access strategy requires. It’s a journey, and we’re with our clients every step of the way to ensure the most favorable outcome.
New From Our Blog
More
Changes to New York’s Rebate Programs
Manufacturers are often intimidated when directed by New York to participate in Medicaid, due to the uniqueness of their programs. We aim to eliminate confusion in navigating these processes to resolution. In this blog post, we’ll walk you through a summary of the most recent changes to the New York Medicaid programs.
Read More
State Medicaid Programs Retake Pharmacy Controls
State Medicaid programs’ relationships with managed care organizations that serve Medicaid recipients continue to evolve. Just when it appears that trends are slowing or stabilizing, a new method is introduced. The latest development could overlap existing state controls to bring even more pharmacy control back to state management.
Read More
Reimbursement Challenges with High-Cost Inpatient Drugs
The management and reimbursement of inpatient drug costs in Medicaid programs are pivotal topics, especially with the proliferation of high-cost therapies. The emergence of expensive inpatient drugs, such as cell and gene therapies, have challenged Diagnosis Related Groups (DRGs), the traditional bundled payment system used by hospitals.
Read More